Exozymes (EXOZ) Income from Continuing Operations (2023 - 2026)
Exozymes (EXOZ) posted quarterly Income from Continuing Operations of 2760241.0 for Q4 2025, down 356.17% year-over-year from 1077514.94 in Q4 2024, and down 20.69% quarter-over-quarter from 2286991.0 in Q3 2025.
Exozymes (EXOZ) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Exozymes (EXOZ) has reported Income from Continuing Operations for 3 consecutive years, with 2760241.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations fell 356.17% year-over-year to 2760241.0; the TTM figure through Dec 2025 stood at 9263939.0 (down 100.07% YoY), while the FY2025 annual figure was 9158734.0, down 97.79% from the prior year.
- Income from Continuing Operations eased to 2760241.0 in Q4 2025 per EXOZ's latest filing, from 2286991.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 520596.0 in Q3 2023 and bottomed at 2760241.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 1547128.6 across 3 years, with a median of 1508451.0 in 2024.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 42.72% — and 2025, when it sank 356.17%.
- Exozymes' Income from Continuing Operations stood at 1056297.0 in 2023, then surged by 42.72% to 605094.0 in 2024, then plunged by 356.17% to 2760241.0 in 2025.
- Business Quant data shows EXOZ's Income from Continuing Operations at 2760241.0 in Q4 2025, 2286991.0 in Q3 2025, and 2360286.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Exozymes | 62.35 Mn | 62.35 Mn | - | -2.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.88 Mn |
| Dec 31, 2025 | -2.76 Mn |
| Sep 30, 2025 | -2.29 Mn |
| Jun 30, 2025 | -2.36 Mn |
| Mar 31, 2025 | -1.86 Mn |
| Dec 31, 2024 | -605,094.00 |
| Sep 30, 2024 | -1.66 Mn |
| Jun 30, 2024 | -1.36 Mn |
| Mar 31, 2024 | -1.01 Mn |
| Dec 31, 2023 | -1.06 Mn |
| Sep 30, 2023 | -520,596.00 |